Does roflumilast decrease exacerbations in severe COPD patients not controlled by inhaled combination therapy? The REACT study protocol.
Peter M.A. Calverley,Fernando J. Martinez,Leonardo M. Fabbri,Udo-Michael Goehring,Klaus F. Rabe +4 more
TL;DR: It is hypothesized that because roflumilast (a phosphodiesterase-4 inhibitor) has a different mode of action to bronchodilators and inhaled corticosteroids, it may provide additional benefits when added to these treatments in frequent exacerbators.
read more
Abstract: Background Many patients with chronic obstructive pulmonary disease (COPD) continue to suffer exacerbations, even when treated with maximum recommended therapy (eg, inhaled combinations of long-acting β2-agonist and high dose inhaled corticosteroids, with or without a long-acting anticholinergic [long-acting muscarinic antagonist]) Roflumilast is approved to treat severe COPD in patients with chronic bronchitis--and a history of frequent exacerbations--as an add-on to bronchodilators Purpose The REACT (Roflumilast in the Prevention of COPD Exacerbations While Taking Appropriate Combination Treatment) study (identification number RO-2455-404-RD, clinicaltrials gov identifier NCT01329029) will investigate whether roflumilast further reduces exacerbations when added to inhaled combination therapy in patients still suffering from frequent exacerbations Patients and methods REACT is a 1-year randomized, double-blind, multicenter, phase III/IV study of roflumilast 500 μg once daily or placebo on top of a fixed long-acting β2-agonist/inhaled corticosteroid combination A concomitant long-acting muscarinic antagonist will be allowed at stable doses The primary outcome is the rate of moderate or severe COPD exacerbations Using a Poisson regression model with a two-sided significance level of 5%, a sample size of 967 patients per treatment group is needed for 90% power COPD patients with severe to very severe airflow limitation, symptoms of chronic bronchitis, and at least two exacerbations in the previous year will be recruited Conclusion It is hypothesized that because roflumilast (a phosphodiesterase-4 inhibitor) has a different mode of action to bronchodilators and inhaled corticosteroids, it may provide additional benefits when added to these treatments in frequent exacerbators REACT will be important to determine the role of roflumilast in COPD management Here, the design and rationale for this important study is described
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Escalation and De-escalation of Therapy in COPD: Myths, Realities and Perspectives.
TL;DR: It is strongly believed that it is always better to avoid a therapeutic step-up progression when it is not needed rather than being forced subsequently into a step-down approach in which the outcome is always unpredictable.
Potential mechanisms to explain how LABAs and PDE4 inhibitors enhance the clinical efficacy of glucocorticoids in inflammatory lung diseases.
Mark A. Giembycz,Robert Newton +1 more
TL;DR: A state-of-the-art appraisal, including unresolved and controversial issues, of how cAMP-elevating drugs and inhaled glucocorticoid/LABA combination therapy interact at a molecular level to deliver enhanced anti-inflammatory benefit over inhaled glucose-based monotherapy is provided.
Management and prevention of exacerbations of COPD
TL;DR: The addition of azithromycin to usual COPD therapy prevents exacerbations, although it may prolong the Q-T interval and increase the risk of death from cardiovascular disease in patients prone to arrhythmia.
References
Global initiative for chronic obstructive lung disease.
Lynn B. Gerald,William C. Bailey +1 more
TL;DR: Representatives from many countries serve as a network for the dissemination and implementation of programs for diagnosis, management, and prevention of COPD.
3.8K
Regression analysis of multivariate incomplete failure time data by modeling marginal distributions
L. J. Wei,Danyu Lin,L. Weissfeld +2 more
TL;DR: In this paper, the authors consider the regression analysis of multivariate failure time observations and formulate each marginal distribution of the failure times by a Cox proportional hazards model, which is shown to be asymptotically jointly normal with a covariance matrix that can be consistently estimated.
1.9K
Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease
Juan José Soler-Cataluña,Miguel Ángel Martínez-García,P Román Sánchez,E Salcedo,Miriam Navarro,R Ochando +5 more
TL;DR: For the first time, severe acute exacerbations of COPD have an independent negative impact on patient prognosis, and Mortality increases with the frequency of severe exacerbations, particularly if these require admission to hospital.
1.8K
Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease: Thorax 2005;60:925–31
Juan José Soler-Cataluña,Miguel Ángel Martínez-García,P Román Sánchez,E Salcedo,Miriam Navarro,R Ochando +5 more
TL;DR: This study shows for the first time that severe acute exacerbations of COPD have an independent negative impact on patient prognosis, particularly if these require admission to hospital.
The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial.
Nicholas R. Anthonisen,Melissa Skeans,Robert A. Wise,Jure Manfreda,Richard E. Kanner,John E. Connett +5 more
TL;DR: The smoking cessation program was associated with cumulative reduced decline in lung function (FEV1) that was largest in participants who stopped smoking early in the study; inhaled ipratropium produced a small noncumulative increase in FEV1 that disappeared when the drug was withdrawn.
1.1K